{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:43Z","timestamp":1791920923557,"version":"4.3.4"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T00:00:00Z","timestamp":1560038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Altered DNA methylation and histone acetylation in lymphoma provided the rationale for using vorinostat (SAHA), cladribine and rituximab (SCR) in non\u2010Hodgkin lymphomas (NHL) in this phase 1\u20132 study (NCT00764517). Treatment included cladribine 5\u00a0mg\/m<jats:sup>2<\/jats:sup> intravenously (IV) (days 1\u20135), rituximab 375\u00a0mg\/m<jats:sup>2<\/jats:sup> IV (weekly 4\u00d7 for cycle 1 and 1\u00d7\/month) and vorinostat orally once daily (days 1\u201314) every 28\u00a0days for up to six cycles. Phase 1 included relapsed patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a010) in a standard 3\u00a0+\u00a03 dose escalation design (vorinostat: 200, 300 and 400\u00a0mg). No dose\u2010limiting toxicities were seen. The phase 2 dose for vorinostat was 400\u00a0mg po (days 1\u201314). The majority of phase 2 patients had mantle cell lymphoma (MCL) (<jats:italic>n<\/jats:italic>\u00a0=\u00a057; 39 previously untreated, 10 relapsed). The primary objective was objective response rate [complete response (CR)\u00a0+\u00a0partial response] which was 39% (7\/18) in relapsed patients and 97% (38\/39) with 80% (31\/39) attaining a CR in previously untreated MCL. At a median follow\u2010up of 42\u00a0months, median progression\u2010free survival (PFS) and overall survival (OS) for relapsed NHL were 19\u00b75 [95% confidence interval (CI): 2\u00b70\u201333\u00b70] and 25\u00b70 (95% CI: 12\u00b70\u201345\u00b70)\u00a0months respectively. Median PFS for previously untreated MCL was 84\u00b70\u00a0months; OS could not be estimated. Toxicities were primarily haematological.<\/jats:p>","DOI":"10.1111\/bjh.16008","type":"journal-article","created":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T23:33:01Z","timestamp":1560123181000},"page":"845-854","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Phase 1\u20132 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B\u2010cell non\u2010Hodgkin lymphoma and previously untreated mantle cell lymphoma"],"prefix":"10.1111","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-438X","authenticated-orcid":false,"given":"Stephen E.","family":"Spurgeon","sequence":"first","affiliation":[{"name":"Center for Hematologic Malignancies Knight Cancer Institute at Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Sharma","sequence":"additional","affiliation":[{"name":"Penn State Hershey Cancer Institute Hershey PA USA"},{"name":"Cassidy Cancer Center Winter Haven FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Claxton","sequence":"additional","affiliation":[{"name":"Penn State Hershey Cancer Institute Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ehmann","sequence":"additional","affiliation":[{"name":"Penn State Hershey Cancer Institute Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Pu","sequence":"additional","affiliation":[{"name":"Upstate Cancer Center, SUNY Upstate Medical University Syracuse NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Shimko","sequence":"additional","affiliation":[{"name":"Penn State Hershey Cancer Institute Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"August","family":"Stewart","sequence":"additional","affiliation":[{"name":"Penn State Hershey Cancer Institute Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies Knight Cancer Institute at Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundula","family":"Palmbach","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies Knight Cancer Institute at Oregon Health &amp; Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5979-0479","authenticated-orcid":false,"given":"Francis","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Latour","sequence":"additional","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiYi","family":"Chen","sequence":"additional","affiliation":[{"name":"Biostatistics Shared Resource Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomi","family":"Mori","sequence":"additional","affiliation":[{"name":"Biostatistics Shared Resource Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainul","family":"Hasanali","sequence":"additional","affiliation":[{"name":"Penn State Hershey Cancer Institute Hershey PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot M.","family":"Epner","sequence":"additional","affiliation":[{"name":"Penn State Hershey Cancer Institute Hershey PA USA"},{"name":"Enloe Medical Center Chico CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2016-08-736066","article-title":"HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti\u2010CD20 monoclonal antibodies","volume":"130","author":"Bobrowicz M.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07426.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656628"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.10.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14480"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-010-0527-3"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-4-4"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28321"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa5079"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.437"},{"key":"e_1_2_8_16_1","first-page":"153","article-title":"Rituximab maintenance after first\u2010line immunochemotherapy in mantle cell lymphoma: long\u2010term follow\u2010up of the Randomized European MCL Elderly trial","volume":"130","author":"Hoster E.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23537"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx814"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232868"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2443"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257485"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0483"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.282"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0245-y"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.09.001"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-859769"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.09.008"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2008.07.001"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.157"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.04.007"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903071038"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.575489"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30185-5"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01360.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(02)01486-7"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-2026-y"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0125"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16008","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T23:14:43Z","timestamp":1694301283000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,9]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/bjh.16008"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16008","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,9]]},"assertion":[{"value":"2019-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}